drugset
drugset / Trial / NCT04718376

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

NCT04718376 ↗

Phase 1 Terminated 56 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.

Timeline

Start
2021-01-12
Primary completion
2023-05-22
Completion
2023-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous

Indications

No indication recorded.